FORT WORTH, Texas--(BUSINESS WIRE)--April 25, 2005--Alcon, Inc., (NYSE:ACL) announced the launch of the AcrySof(R) ReSTOR(R) Intraocular Lens (IOL) at a press conference during the American Society of ...

Basel, Switzerland, April 16, 2015-Alcon, the global leader in eye care and a division of Novartis, has received approval from the US Food and Drug Administration (FDA) for its AcrySof ® IQ ReSTOR ® ...

For years, patients who underwent cataract surgery had to wear glasses or contact lenses afterwards to see clearly. The newly developed ReSTOR® lens has overcome this problem, allowing patients to see ...

Please provide your email address to receive an email when new articles are posted on . We now have U.S. Food and Drug Administration approval of six presbyopic IOLs: the Advanced Medical Optics ...

According to our data and model for cataract, bilateral ReSTOR ® (2 × €500) implants were always a cost-saving alternative to monofocal IOL implants when viewed from a societal perspective. Our ...

(RTTNews) - Alcon, a division of Novartis, announced it has received approval from the US FDA for its AcrySof IQ ReSTOR +2.5 Multifocal Toric intraocular lens with ACTIVEFOCUS optical design for ...

Here is the current list (as of Feb. 9, 2011) of posterior chamber (P-C) and anterior chamber (A-C) intraocular lenses recognized by CMS. – Crystalens, manufactured by Eyeonics (now Bausch & Lomb). – ...

Here are 17 facts and business and legal issues about premium intraocular lenses, a recent technology that can free many cataract surgery patients from having to wear eyeglasses. 1. In one of the few ...

Please provide your email address to receive an email when new articles are posted on . Newer IOL designs are getting better and better, giving a wider range of vision, from near to far, with higher ...

If you are over the age of 65, Medicare will cover the cost of cataract surgery along with a conventional "monofocal" IOL. Patients electing monofocal IOLs typically have both eyes corrected for clear ...

Intraocular lenses (IOLs), implanted in the eye as treatment for cataracts or myopia, are a growing global market in an ageing population, one estimated to be worth more than $4.5 billion by 2022.